MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1802)	12/4/2007 2:25:46 AM
From: Icebrg	Read Replies (1) of 1826

Wachovia Starts MGI Pharma (MOGN) at Market Perform 12-03-2007 05:43:02 PM Wachovia initiates coverage on MGI Pharma (Nasdaq: MOGN) with a Market Perform rating and a $31 to $37 valuation range. The firm said it does not understand the choice by MGI's management to seek strategic alternative at this time, as Wachovia sees MGI's fundamentals improving in the first half of 2008.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next